Appendix 4G and Corporate Governance Statement 19 August 2022 by Audrey Thomson Appendix 4G and Corporate Governance Statement 2022
Report on Activities for the Quarter ended 30 June 2022 28 July 2022 by Audrey Thomson Report on Activities for the Quarter Ended 30 June 2022
Positive FDA Guidance for COVID-19 Clinical Program 30 May 2022 by Audrey Thomson Positive FDA Guidance for COVID-19 Clinical Program
BIT225 Effective Against Established SARS-CoV-2 in Animals 2 May 2022 by Audrey Thomson BIT225 Effective Against Established SARS-CoV-2 in Animals
Report on Activities for the Quarter ended 31 March 2022 26 April 2022 by Audrey Thomson Report on Activities for the Quarter Ended 31 March 2022
Confirmation of BIT225 Effectiveness Against COVID-19 in Animals 17 March 2022 by Audrey Thomson Confirmation of BIT225 Effectiveness Against COVID-19 in Animals
Half-year Report 31 December 2021 23 February 2022 by Audrey Thomson Half-year Report 31 December 2021